西黄胶囊联合放疗在鼻咽癌治疗中的临床疗效

目的:探讨西黄胶囊联合放疗在鼻咽癌患者中的临床治疗效果。方法:选取2012年4月—2014年4月本院诊治的80例鼻咽癌患者资料进行分析,采用随机数字法将患者分为对照组和实验组,对照组采用单一放疗治疗,实验组在对照组治疗基础上联合西黄胶囊治疗,比较两组治疗效果。结果:实验组55%治疗效果理想,高于对照组(42.5%)(P0.05);实验组82.5%临床获益高于对照组(P0.05);两组患者治疗前血清T细胞亚群水平,如:CD3+,CD4+,CD8+以及CD4+/CD8+等指标差异不显著;实验组治疗后CD3+,CD4+,CD8+以及CD4+/CD8+等指标显著低于对照组(P0.05);实验组不良反应发生率为32.5%,低于对照组(42.5%)(P0.05);实验组ADL评分,躯体功能评分,心理功能评分,社会功能评分,均高于对照组(P0.05)。结论:鼻咽癌患者在放疗基础上联合西黄胶囊治疗效果理想,能够提高临床疗效,降低不良反应发生率,值得推广使用。

Xihuang Capsule Combined with Radiotherapy in Patients with Nasopharyngeal Carcinoma

Objective: To explore the Xihuang capsule in combination with radiotherapy clinical outcomes in patients with nasopharyngeal carcinoma. Method: From April 2012 to April 2014 in our hospital 80 patients with nasopharyngeal carcinoma were analyzed data, the patients were randomly divided into a control group method and the experimental group and the control group using a single radiation treatment, the experimental group combined with the control group on the basis of Xihuang capsule treatment were compared treatment. Result: 55% of the treatment group, the results are satisfactory, the control group (42.5%) (P<0.05). The experimental group was 82.5% higher than clinical benefit (P<0.05). two groups of patients before treatment serum T cell subsets group level, such as:indexes were CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺, which are not significant. The experimental group after treatment CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ other indicators significantly lower than the control group (P<0.05). The adverse reactions in the experimental group was 32.5%, lower than in the control group (42.5%) (P<0.05), ADL score in the experimental group, physical function score, mental function scores, social function scores were higher (P<0.05). Conclusion: Capsule NPC patients in radiotherapy combined with western treatment based on the desired therapeutic effect, can improve clinical outcomes and reduce the incidence of adverse reactions, should be introduced.